Home / Categories / By country / America / North America / Canada / HCP - Canada
Click to view full size image
Click here for details on how to download this file to your desktop.


Where can you turn for help in preventing MENB?

Serogroup B has become the most common invasive meningococcal disease (IMD) serogroup to affect Canadians (2011).

Percentage of reported IMD cases by age and serogroup, Canada (2007-2011)

AMONG INFANTS <1 year of age

AMONG CHILDREN 1-4 years of age

AMONG ADOLESCENTS 15-19 years of age


The first and only vaccine indicated for active immunization against invasive meningococcal disease caused by serogroup B strains.

BEXSERO is indicated for active immunization of individuals from 2 months through 17 years old against invasive disease caused by N. meningitidis serogroup B strains.


Multicomponent Meningococcal B Vaccine (recombinant, adsorbed)

Be informed. Be immunized.

Other ads from this campaign

Brand: Bexsero
Country/Market: Canada, North America
Target: Healthcare Professional (HCP)
Tagline: Be informed. Be immunized.
Size/duration: Single-page
CMAJ-JAMC - May 19, 2015

See more Bexsero ads here
Rate this file (No vote yet)
File information
Download:Available for logged-in users with full-size access enabled.
Keywords:fd57SORu , 55715 , xjbQfRer , Single-page , healthcare category , hcpCanada , Canada , Healthcare Professional (HCP) , Print ad , English , CMAJMay1915 , Where can you turn for help in preventing MENB? , Bexsero , Bexsero brand , Meningococcal Group B Vaccine Novartis , Vaccines And Diagnostics , adsorbed , bacterial meningitis , component , Diagnostics , Inoculation , MenB , Meningitis B , Prevention , Prophylaxis , protective , rDNA , septicaemia , Vaccine , Vaccines
Filesize:6421 KiB
Date added:May 24, 2015
Dimensions:3684 x 5000 pixels
Displayed:67 times
My Collection:Add to collection
About Subscriptions Contact us Twitter LinkedIn